1,103
Participants
Start Date
March 31, 2015
Primary Completion Date
January 31, 2018
Study Completion Date
March 31, 2018
Fluoropyrimidine (capecitabine or 5-fluorouracil)
Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam
Wilhelmina Hospital Assen, Assen
Amphia Hospital, Breda
Reinier de Graaf Hospital, Delft
Deventer Hospital, Deventer
Hospital Gelderse Vallei, Ede
Catharina Hospital, Eindhoven
Leiden University Medical Center, Leiden
Maastricht University Medical Center, Maastricht
Canisius-Wilhelmina Hospital, Nijmegen
Laurentius Hospital, Roermond
Bravis Hospital, Roosendaal
Erasmus MC, Rotterdam
Franciscus Gasthuis & Vlietland, Rotterdam
Haga Hospital, The Hague
Medical Center Haaglanden, The Hague
University Medical Center Utrecht, Utrecht
The Netherlands Cancer Institute
OTHER